SU11. Amisulpride Augmentation of Clozapine for Treatment-Refractory Schizophrenia: The AMICUS Study

Thomas R. E. Barnes(Unknown), Tim Amos(University of Bristol), David Osborn(University College London), Peter Haddad(Deakin University), Mariwan Husni(Central and North West London NHS Foundation Trust), Louise Marston(University College London), Pavel Fridrich(South Essex Partnership University Foundation NHS Trust), Verity C. Leeson(Centre for Mental Health), Carol Paton(Oxleas NHS Foundation Trust), Patrick Keown, Khalid Iqbal(Leibniz Institute for Prevention Research and Epidemiology - BIPS), Vineet Singh, Rameez Zafar(Lincolnshire Partnership NHS Foundation Trust), Hemant Bagalkote(Nottinghamshire Healthcare NHS Foundation Trust), Raj Kumar(Tees, Esk and Wear Valleys NHS Foundation Trust), Zachary Fitzgerald(Barwon Health)
Schizophrenia Bulletin
March 1, 2017
10.1093/schbul/sbx024.010
Cited by 3

Related Papers

Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials
|American Journal of Psychiatry|2003|491
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
|The British Journal of Psychiatry|2017|486
Suicide within 12 months of contact with mental health services: national clinical survey
|BMJ|1999|475
Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study
|BMJ|2015|401
A systematic review and meta-analysis of premature mortality in bipolar affective disorder
|Acta Psychiatrica Scandinavica|2015|370